Pfizer's high-stakes bet on antibody-drug conjugates (ADCs) has hit a speed bump. The pharma giant a...
Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial
Pfizer's high-stakes bet on antibody-drug conjugates (ADCs) has hit a speed bump. The pharma giant announced Monday that sigvotatug vedotin, the first new...
Author: Fierce Biotech
Read Original Article